ArticleBrain and behavior2025
Usefulness of the Support Video "Talking Picture Book" for Overcoming Hesitancy to Start Galcanezumab Therapy.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study.Drugs - real world outcomes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundGalcanezumab, approved in April 2021, is the first humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand to become available in Japan, but some patients with migraine are hesitant to start an anti-CGRP antibody for a variety of reasons, particularly its high price. To address this, a video in Japanese called "Talking Picture Book," which aims to alleviate patients' concerns about the anti-CGRP antibody, was released as support material in Japan in March 2022.
methodBetween December 2022 and May 2023, we conducted a questionnaire survey of 34 consecutive patients who had just viewed the video in order to evaluate its effectiveness in persuading hesitant patients to start an anti-CGRP antibody.
resultOf these 34 patients, 79.8% gained a better understanding of migraine, 61.8% expressed a willingness to try galcanezumab, and 52.4% (11 patients) actually started the anti-CGRP antibody. The number of mean monthly migraine days was significantly greater in those 11 patients than in the others. Multivariable logistic analysis of factors contributing to the decision to start anti-CGRP antibody treatment revealed significant associations with monthly migraine days (odds ratio, 1.30; p = 0.01) and patients' willingness to try anti-CGRP antibodies (odds ratio, 9.82; p = 0.04).
conclusionThis material was particularly useful for patients with a high number of monthly migraine days who had been hesitant to start the therapy. "Talking Picture Book" is a useful material that complements physicians' explanations of the therapy, and it is desirable that such video materials be adapted for use in other countries in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.